GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
GenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results
February 28, 2017 4:05 PM ESTFourth Quarter Revenue Increased 13% Versus Prior Year to $14.9 million
Full Year Revenue Grew by 25% to $49.3 million
Submitted FDA 510(k) Applications for ePlex Instrument and Respiratory Pathogen Panel
Ended 2016 with More Than 55 Customer Agreements, Representing Over 85 ePlex Instruments
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2016.
Revenue for the fourth quarter of 2016 was $14.9... More
